HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.

By FierceBiotech · Apr 25, 2026 · via FierceBiotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Image: FierceBiotech

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Amneal to buy a biosimilar company; Samsung Bio workers protest
DealsEndpoints News ↗
Amneal to buy a biosimilar company; Samsung Bio workers protest
Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals t…
Apr 23, 2026
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
DealsBriefing
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
Apr 22, 2026
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
DealsFierceBiotech ↗
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
Apr 21, 2026